Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity